Speaker: Craig H. Mallinckrodt, Eli Lilly
A structured framework for assessing sensitivity to missing data assumptions in longitudinal clinical trials
Co-authors: Q. Lin and M. Molenberghs;
Pharmaceutical Statistics, Volume 12, Issue 1, Pages 1–6, January/February 2013 Abstract | Paper+ | Slides
Speaker: Scott W. Andersen, Eli Lilly
On the practical application of mixed effects models for repeated measures to clinical trial data
Co-author: Brian A. Millen;
Pharmaceutical Statistics, Volume 12, Issue 1, Pages 7–16, January/February 2013 Abstract | Paper+ | Slides
+ Papers available to view throughout 2013.
For a flier advertising the event, please click here.
Speaker: Craig H. Mallinckrodt, Eli Lilly
A structured framework for assessing sensitivity to missing data assumptions in longitudinal clinical trials
Co-authors: Q. Lin and M. Molenberghs;
Pharmaceutical Statistics, Volume 12, Issue 1, Pages 1–6, January/February 2013 Abstract | Paper+ | Slides
Speaker: Scott W. Andersen, Eli Lilly
On the practical application of mixed effects models for repeated measures to clinical trial data
Co-author: Brian A. Millen;
Pharmaceutical Statistics, Volume 12, Issue 1, Pages 7–16, January/February 2013 Abstract | Paper+ | Slides
+ Papers available to view throughout 2013.
For a flier advertising the event, please click here.
Speaker: Craig H. Mallinckrodt, Eli Lilly
A structured framework for assessing sensitivity to missing data assumptions in longitudinal clinical trials
Co-authors: Q. Lin and M. Molenberghs;
Pharmaceutical Statistics, Volume 12, Issue 1, Pages 1–6, January/February 2013 Abstract | Paper+ | Slides
Speaker: Scott W. Andersen, Eli Lilly
On the practical application of mixed effects models for repeated measures to clinical trial data
Co-author: Brian A. Millen;
Pharmaceutical Statistics, Volume 12, Issue 1, Pages 7–16, January/February 2013 Abstract | Paper+ | Slides
+ Papers available to view throughout 2013.
For a flier advertising the event, please click here.
Speaker: Craig H. Mallinckrodt, Eli Lilly
A structured framework for assessing sensitivity to missing data assumptions in longitudinal clinical trials
Co-authors: Q. Lin and M. Molenberghs;
Pharmaceutical Statistics, Volume 12, Issue 1, Pages 1–6, January/February 2013 Abstract | Paper+ | Slides
Speaker: Scott W. Andersen, Eli Lilly
On the practical application of mixed effects models for repeated measures to clinical trial data
Co-author: Brian A. Millen;
Pharmaceutical Statistics, Volume 12, Issue 1, Pages 7–16, January/February 2013 Abstract | Paper+ | Slides
+ Papers available to view throughout 2013.
For a flier advertising the event, please click here.
Speaker: Craig H. Mallinckrodt, Eli Lilly
A structured framework for assessing sensitivity to missing data assumptions in longitudinal clinical trials
Co-authors: Q. Lin and M. Molenberghs;
Pharmaceutical Statistics, Volume 12, Issue 1, Pages 1–6, January/February 2013 Abstract | Paper+ | Slides
Speaker: Scott W. Andersen, Eli Lilly
On the practical application of mixed effects models for repeated measures to clinical trial data
Co-author: Brian A. Millen;
Pharmaceutical Statistics, Volume 12, Issue 1, Pages 7–16, January/February 2013 Abstract | Paper+ | Slides
+ Papers available to view throughout 2013.
For a flier advertising the event, please click here.
Speaker: Craig H. Mallinckrodt, Eli Lilly
A structured framework for assessing sensitivity to missing data assumptions in longitudinal clinical trials
Co-authors: Q. Lin and M. Molenberghs;
Pharmaceutical Statistics, Volume 12, Issue 1, Pages 1–6, January/February 2013 Abstract | Paper+ | Slides
Speaker: Scott W. Andersen, Eli Lilly
On the practical application of mixed effects models for repeated measures to clinical trial data
Co-author: Brian A. Millen;
Pharmaceutical Statistics, Volume 12, Issue 1, Pages 7–16, January/February 2013 Abstract | Paper+ | Slides
+ Papers available to view throughout 2013.
For a flier advertising the event, please click here.
Upcoming Events
Joint PSI/EFSPI Visualisation SIG 'Wonderful Wednesday' Webinars
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
The event will open with an overview on drug development in women’s health from a clinician perspective. This talk is followed by talks about statistical challenges when planning IVF studies and analysing the menstrual cycles.
This webinar will provide an overview of surrogacy for licensing and reimbursement. In turn, the need of extensions of the SPIRIT and CONSORT statement will be defined and outlined, with case studies to support.
Joint PSI/EFSPI Pre-Clinical SIG Webinar: Virtual Control Groups in Toxicity Studies
Lea Vaas will present how replacement of concurrent control animals by Virtual Control Groups (VCGs) in systemic toxicity studies may help in contributing to the 3R's principle of animal experimentation: Reduce, Refine, Replace.
Joint PSI/EFSPI Data Science SIG Webinar: Developing Digital Measures (Digital Biomarkers) in Drug Development – insights from Mobilise D consortium
We will share a brief overview of what Mobilise D is and why it is an important step stone in the development of digital biomarkers, and how Mobilise D outputs can be relevant for you.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
PSI Webinar: Development of Gene Therapies: Strategic, Scientific, Regulatory and Access Considerations
This webinar will cover the history of cell/gene therapy, major regulatory advances, the role of quantitative scientists in drug development of these novel therapeutics, and discuss opportunities for innovation and product advancement.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
PSI Introduction to Industry Training (ITIT) Course - 2024/2025
An introductory course giving an overview of the pharmaceutical industry and the drug development process as a whole, aimed at those with 1-3 years' experience. It comprises of six 2-day sessions covering a range of topics including Research and Development, Toxicology, Data Management and the Role of a CRO, Clinical Trials, Reimbursement, and Marketing.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
Statisticians in the Pharmaceutical Industry Executive Office: c/o MCI UK Ltd | Unit 24/22 South | Building 4000 | Langstone Park| Langstone Road | Havant | PO9 1SA | UK